For most of medical history, treatment decisions were based on population averages. A patient with a given condition received the same drug at the same dose as every other patient with that condition, adjusted only for body weight or kidney function. Responses varied enormously, and no one fully understood why. Precision medicine is the effort to change that.
The term refers to an approach that tailors medical treatment to the individual characteristics of each patient — most importantly, their genetic profile. Advances in genome sequencing have made it possible to read a person’s entire DNA code for a fraction of the cost it required two decades ago. This genetic information can reveal which drugs a patient is likely to metabolize quickly or slowly, which mutations are driving their cancer, and which preventive measures are most relevant to their personal risk profile.
Oncology has been the proving ground for precision medicine. Tumors are no longer classified solely by where they originate in the body. A lung cancer driven by a specific mutation in the EGFR gene responds to very different drugs than a lung cancer driven by an ALK rearrangement. Targeted therapies designed to block these specific molecular drivers have dramatically improved outcomes for patients whose tumors carry the relevant genetic changes.
Beyond cancer, pharmacogenomics — the study of how genes affect drug response — is beginning to influence prescribing in cardiology, psychiatry, and pain management. Some patients carry variants in a gene called CYP2D6 that cause them to break down certain antidepressants or opioids far more rapidly than average, rendering standard doses ineffective. Others are poor metabolizers, meaning standard doses accumulate to toxic levels. Genetic testing before prescribing could prevent many of these adverse events.
The challenges ahead are significant. Genetic data raises serious privacy concerns. Access to precision medicine remains unequal, concentrated in wealthy countries and major academic centers. And the biological complexity of most diseases means that genetics alone rarely tells the whole story. But the direction is clear: medicine is moving, however unevenly, toward treating the person rather than the diagnosis.